Abstract
OBJECTIVES: To explore the effect of ligustrazine phosphate tablets combined with cerebroside carnosine on neurological function and serum inflammatory factors among patients with ischemic cerebrovascular disease. METHODS: This was a quasi-experimental study. From March 2019 to February 2022, 126 patients were non-randomly divided into control (n = 63) and intervention (n = 63) groups. The control group received routine treatment such as encephaloside and carnosine, while the intervention group was treated with ligustrazine phosphate tablets and brain glycoside carnosine for 2 weeks. Serum S-100β protein, nerve growth factor (NGF), inflammatory factors [tumor necrosis factor-α (TNF-α) and C-reactive protein (CRP)], National Institutes of Health Stroke scale (NIHSS) and and Activities of Daily Living (ADL) scale were assessed before and after the intervention. RESULTS: After treatment, the level of S-100β in the intervention group was lower, and the level of NGF was significantly higher than in the control group. The levels of TNF-α and CRP in the intervention group were reduced. The NIHSS score of the intervention group was lower, and the ADL score was significantly higher than that of the control group. CONCLUSIONS: The combination of ligustrazine phosphate tablets with cerebroside carnosine can improve neurological function, alleviate inflammation, and enhance the quality of life, worthy of clinical promotion.